unique and development of prophylactics and/or therapeutics against the virus represents a significant contribution to agriculture and public health sectors throughout the world. Application: Novel therapeutics for the treatment and prevention of avian influenza.

Development Status: In vitro and early-stage animal studies have been performed.

Inventors: Barry R. O’Keefe and James B. McMahon (NCI).


Licensing Status: Available for non-exclusive or exclusive licensing.

Licensing Contact: Sally Hu, PhD; 301/435–5606; HuS@mail.nih.gov.

Collaborative Research Opportunity: The NCI Molecular Targets Development Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize cyanovirin-N for use against H5N1 influenza. Please contact Betty Tong, PhD at 301–594–4263 or tongb@mail.nih.gov for more information.

Methods for Treating Drug-Resistant HIV–1 Infection

Description of Technology: Drug-resistance is a critical factor contributing to the loss of clinical benefit of currently available human immunodeficiency virus-1 (HIV–1) therapies. Accordingly, combination therapies have evolved to address the rapidly evolving virus. However, there has been great concern regarding the growing resistance of HIV–1 strains to current therapies as multi-drug resistance to protease inhibitors is becoming more common. The current technology embodies a breakthrough against this immense obstacle of existing HIV–1 treatments.

Compositions and methods of inhibiting the protease of multi-drug resistant retroviruses such as HIV–1 are available for non-exclusive licensing and commercial development. The antiviral activity of the compound described by the current invention has been established against multi-protease inhibitor-resistant HIV–1 variants and demonstrated effective in patients with widespread resistance to currently available protease inhibitors. In addition, commercial development of this composition has resulted in the production of a novel drug that has recently been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of HIV–1 in patients who are non-responsive to existing antiretroviral therapies.

The available composition retains the unique ability to inhibit drug resistant mutants due to its distinctive points of interaction with the enzyme: the agent tightly binds to the part of the protease substrate binding site, which the virus cannot easily change. Other “conventional” protease inhibitors bind to other parts of the protease substrate binding site, which the virus can relatively easily change, rendering these drugs ineffective after repeated use. Therefore, the current technology represents a highly effective method of targeting drug resistant HIV–1 strains.

Applications: (1) Novel therapeutics for the treatment of drug-resistant HIV; (2) Safe and effective methods for administration of anti-HIV/AIDS drugs.

Development Status: Clinical trials have been performed with Prezista™ (darunavir), a drug resulting from development of the present technology, which has received accelerated approval from the FDA.

Inventors: John W. Erickson (SAIC/NCI), Sergei V. Gulnik (SAIC/NCI), Hiroaki C. Mitsuya (NCI), and Arun K. Ghosh.

Related Publications:


Licensing Contact: Sally Hu, PhD; 301/435–5606; HuS@mail.nih.gov.


Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E6–19050 Filed 11–9–06; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health, Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Advisory Committee to the Director, NIH.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Advisory Committee to the Director, NIH.

Date: December 1, 2006.

Time: 8:30 a.m. to 5 p.m.

Agenda: Among the topics proposed for discussion are: (1) NIH Director’s Report; (2) NIH Director’s Council of Public Representatives Liaison Report; (3) Institute Director’s Report; and (4) Work Group on Outside Awards for NIH Employees.

Place: National Institutes of Health, Building 31, C Wing, Conference Room 6, 9000 Rockville Pike, Bethesda, MD 20892.

Contact Person: Shelly Pollard, ACD Coordinator, National Institutes of Health, 9000 Rockville Pike, Building 31, Room 5B64, Bethesda, MD 20892. (301) 496–0959. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a
government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit.

Information is also available on the Institute’s Center’s home page: http://www.nih.gov/about/director/acad.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)


Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 06–9150 Filed 11–9–06; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.


Date: November 29, 2006.

Time: 4:30 p.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: David George, PhD, Director, Office of Scientific Review, National Institute of Biomedical Imaging and Bioengineering, 6707 Democracy Blvd., Suite 920, Bethesda, MD 20892, 301–496–8633, george1@mail.nih.gov.

Dated: November 2, 2006.

Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 06–9153 Filed 11–9–06; 8:45 am]

BILLING CODE 4140–01–M